

**DATA SHEET**  
**Hsa-miR-532-5p fluoresceinated oligo probe**

**Catalog No.**  
**HM532-5p-100**

**Description**  
One vial of 0.650 ml of probe in hybridization buffer

**Analyte Specific Reagent. Analytical and performance characteristics are not established.**

Doc. No. 932-HM532-5p-100

Rev. B

Date of release: 18-Aug-2020

**Description**

The Hsa-miR-532-5p probe has been designed from mature human miR-532-5p sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

**Specifications**

The Hsa-miR-532-5p identifies mature miR-532-5p sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

**Storage and Handling**

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

**Precautions:**

For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

**Quality Control**

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

**References**

1. Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Urban N, Kiviat N: DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. *Gynecol Oncol* 2008, 111:320–329.
2. Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. *World J Surg Oncol*. 2012 Aug 27;10:174.
3. Venkatesan N, Deepa PR, Khetan V, Krishnakumar S. Computational and in vitro Investigation of miRNA-Gene Regulations in Retinoblastoma Pathogenesis: miRNA Mimics Strategy. *Bioinform Biol Insights*. 2015 May 12;9:89-101.
4. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. *Clin Cancer Res*. 2009 May 1;15(9):2988-94.

**BioGenex Quality Control Testing Conditions**

Parameter	Conditions used
Control Tissue	Ovary (FB-HM532-5p)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues